Scroll Back to Top
Accessibility
Accessibility
April 13, 2026

Integrating ctDNA Liquid Biopsy Tests into Routine Clinical Oncology

As demand grows for rapid, non-invasive, and comprehensive biomarker testing in oncology, liquid biopsies have become a powerful tool for tumor mutation profiling—supporting patient care and serving as an alternative when tissue samples are insufficient, lesions are inaccessible, or timely decisions are needed.
Read more »

Molecular Tumor Board: 68-year-old female with invasive ductal carcinoma of the right breast

In this molecular tumor board discussion, our Medical Affairs team reviews a case of de novo metastatic breast cancer where they emphasize the importance of comprehensive biomarker assessment, including hormone receptor and HER2 biomarkers in guiding therapeutic strategy. Additionally, the discussion highlights the growing role of liquid biopsy in identifying resistance mechanisms and optimizing treatment selection in advanced metastatic breast cancer.

Read more »

Labcorp Perspectives Oncology (Episode 8): FFPE: The workhorse behind NGS testing

In precision oncology, even the smallest specimen can shape critical clinical decisions. In this episode of Labcorp Perspectives: Oncology, Dr. Rebecca Previs speaks with Dr. Kyle Strickland and Dr. Erin Newburn about the essential—but often overlooked—role of tissue stewardship. They explore how pre-analytical choices, workflow design, and advancing technologies influence the quality and clinical value of molecular insights, and how clinicians, researchers, and biopharma partners can maximize limited samples without compromising patient care.

Read more »
December 12, 2025

Expanding access to CGP: Bridging gaps and facilitating integration to reach more patients​

 Comprehensive Genomic Profiling (CGP) is a cornerstone of precision medicine, yet access remains uneven across patient populations, particularly in underserved areas. This workshop will feature a panel of subject matter experts from across the industry who will share insights on expanding accessibility to CGP testing.  We will explore the real-world barriers that limit access to comprehensive genomic profiling - such as geographic disparities, gaps in infrastructure, and the cost of testing. The session will also highlight emerging solutions such as integration with electronic medical records (EMRs) and adoption of scalable technologies to facilitate integration of this testing practice into routine clinical workflows. Attendees will gain insight into tools and digital strategies that help bridge testing gaps and enable broader, more equitable access to increased genomic insights that may help improve outcomes.​
Read more »

Molecular Tumor Board: 64-year-old female with KRAS-mutant lung adenocarcinoma

In our recent Molecular Tumor Board, Labcorp Oncology Medical Affairs team reviewed a complex case of a 64-year-old female with KRAS-mutant lung adenocarcinoma and brain metastases. The team reviewed tissue-based next-generation sequencing and pathology findings, including high PD-L1 expression and confirmation of a moderately to poorly differentiated non-small cell carcinoma consistent with lung adenocarcinoma.

Read more »
Subscribe to Watch